Monoinstitutional real world experience in management of Vinflunine as second line therapy for transitional cell carcinoma of the urothelium

Oncotarget
Giovanni SchinzariCarlo Barone

Abstract

Vinflunine is the only cytotoxic agent tested as a second line therapy in transitional cell carcinoma of the urothelium in a phase III trial. It is not largely employed in clinical practice because of the high incidence of grade 3-4 toxicity. We evaluated efficacy and safety of Vinflunine at the dose of 280 mg/m2every 3 weeks associated with primary prophylaxis with granulocyte growth factors and laxatives for patients progressed after platinum + Gemcitabine. Overall survival was 8.5 months, progression-free survival 4.33 months and response rate 25%, with disease control rate 57.2%. Grade III-IV neutropenia occurred in 10.7% of the patients, grade III-IV anemia and grade III thrombocytopenia in 10.7% and 7.2%, respectively. Among non haematological toxicity, grade I-II constipation was reported in 14.2% of the patients, without grade III-IV adverse events. No discontinuation for toxicity was observed. This study underlines that Vinfluinine at a dose of 280 mg/m2associated with primary prophylaxis for neutropenia and constipation is effective and with a favorable toxicity profile.

References

Feb 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J P SteinD G Skinner
Jul 22, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hans von der MaaseMichael Arning
Aug 19, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J CarlesUNKNOWN Spanish Oncology Genito Urinary Group Study Group
Mar 19, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jaafar BennounaLaurent Nguyen
Aug 19, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joaquim BellmuntHans von der Maase
Oct 9, 2012·Seminars in Oncology·Joaquim Bellmunt, Daniel P Petrylak
Oct 23, 2012·European Urology·Mahul B AminUNKNOWN International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012

❮ Previous
Next ❯

Citations

Mar 27, 2021·Asian Journal of Surgery·Zhongbei YuHaitao Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.